FluoSite Anti-CD38 Antibody, PE-Labeled

This Fluosite(TM) anti-CD38 antibody is a purified monoclonal recombinant antibody, which is labeled with R-Phycoerythrin (PE). This antibody has been tested by flow cytometry for binding to human CD38 on CD38 CHO Cell Line (BPS Bioscience #79615). FluoSite(TM) is a tag-based method for site-specific conjugation of antibodies with fluorophores, ensuring the labeling site is far from the antigen-binding domain to preserve antibody functionality. This precise, consistent labeling ensures the homogeneity of the labeled antibody preparation, making it ideal for flow cytometry and other high-sensitivity applications. CD38 (cyclic ADP-ribose hydrolase 1, ADPRC1) is a glycoprotein and ectoenzyme which plays an important role in regulating intracellular calcium. CD38 is a highly attractive target antigen for immunotherapy because it is highly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells. Expression of CD38 has also been associated with HIV infection, leukemia, and type II diabetes mellitus (T2D). CD38 CAR-T is a T cell product engineered by retroviral transduction to express a fully human CD38-specific CAR (chimeric antigen receptor). In 2015, the FDA approved daratumumab (Darzalex), a breakthrough therapy drug targeting CD38, for the treatment of multiple myeloma.